🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Taxanes combined with trastuzumab and pertuzumab.

Found 108 matching trials

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

PHASE3

This two-arm, randomized, open-label, multicenter study will evaluate the e...

Status

Completed

Location

HonorHealth Research Institute - Bisgrove

Start Date

2014-01-31

Trial ID

NCT01966471

Treatments Being Tested

Trastuzumab Emtansine Trastuzumab Pertuzumab Paclitaxel Epirubicin Doxorubicin Docetaxel Cyclophosphamide 5-Fluorouracil

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

PHASE3

The goal of this multicentre, randomized, double-blind controlled, phase II...

Status

Recruiting

Location

Sun Yat-sen Memorial Hospital,Sun Yat-sen University

Start Date

2023-09-06

Trial ID

NCT06278870

Treatments Being Tested

disitamab vedotin Pyrotinib trastuzumab Pertuzumab taxane drug

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

PHASE3

This is an Asia-Pacific regional, randomized, double-blind, multicenter tri...

Status

Completed

Location

The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)

Start Date

2016-03-14

Trial ID

NCT02586025

Treatments Being Tested

FEC Chemotherapy Surgery Docetaxel Pertuzumab Placebo Trastuzumab

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

PHASE3

This is a multicenter, open label, non-inferiority, randomized controlled c...

Status

Recruiting

Location

Sunyat-sen Memorial Hospital

Start Date

2021-12-20

Trial ID

NCT05159193

Treatments Being Tested

pegylated liposomal doxorubicin (PLD)cyclophosphamide (C)trastuzumab (H)pertuzumab (P)docetaxel (T)docetaxel (T)carboplatin (Cb)trastuzumab (H)pertuzumab (P)

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

PHASE2

Patients with salivary gland carcinoma were divided into groups according t...

Status

Recruiting

Location

Fei Ma

Start Date

2023-08-15

Trial ID

NCT06145308

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

PHASE3

This trial is a registrational Phase III, randomized, open-label, multicent...

Status

Recruiting

Location

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Start Date

2026-04-21

Trial ID

NCT07518173

Treatments Being Tested

BL-M07D1 Pertuzumab Trastuzumab Docetaxel

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

PHASE3

This is a randomized, controlled, open-label, multicenter, phase Ш clinical...

Status

Recruiting

Location

Clinical Trials Information Group

Start Date

2023-07-23

Trial ID

NCT05838066

Treatments Being Tested

Recombinant Humanized Bispecific antibody against HER2，KN026 HB1801 Pertuzumab Trastuzumab Docetaxel

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

PHASE2

Doctors leading this study would like to learn about providing cancer treat...

Status

Recruiting

Location

Lagos State University Teaching Hospital

Start Date

2025-03-18

Trial ID

NCT06348134

Treatments Being Tested

Trastuzumab emtansine Pertuzumab Injection Docetaxel Tamoxifen Letrozole Goserelin

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer

N/A

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a...

Status

Recruiting

Location

Peking University People's Hospital

Start Date

2019-01-01

Trial ID

NCT06722612

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

N/A

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a...

Status

Recruiting

Location

Peking University People's Hospital

Start Date

2019-01-01

Trial ID

NCT06711068

Previous Next